Literature DB >> 22921867

Fibroblast growth factor 23: state of the field and future directions.

Nisan Bhattacharyya1, William H Chong, Rachel I Gafni, Michael T Collins.   

Abstract

Fibroblast growth factor 23 (FGF23) is a bone-derived hormone that regulates and is regulated by blood levels of phosphate and active vitamin D. Post-translational glycosylation by the enzyme GALNT3 and subsequent processing by furin have been demonstrated to be a regulated process that plays a role in regulating FGF23 levels. In physiologic states, FGF23 signaling is mediated by an FGF receptor and the coreceptor, Klotho. Recent work identifying a role for iron/hypoxia pathways in FGF23 physiology and their implications are discussed. Beyond its importance in primary disorders of mineral metabolism, recent work implicates FGF23 in renal disease-associated morbidity, as well as possible roles in cardiovascular disease and skeletal fragility. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22921867      PMCID: PMC3502714          DOI: 10.1016/j.tem.2012.07.002

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  98 in total

1.  A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification.

Authors:  Ilana Chefetz; Raoul Heller; Assimina Galli-Tsinopoulou; Gabriele Richard; Bernd Wollnik; Margarita Indelman; Friederike Koerber; Orit Topaz; Reuven Bergman; Eli Sprecher; Eckhard Schoenau
Journal:  Hum Genet       Date:  2005-11-15       Impact factor: 4.132

2.  Tumor-induced osteomalacia.

Authors:  Suzanne M Jan de Beur
Journal:  JAMA       Date:  2005-09-14       Impact factor: 56.272

3.  Regulation of fibroblast growth factor-23 signaling by klotho.

Authors:  Hiroshi Kurosu; Yasushi Ogawa; Masayoshi Miyoshi; Masaya Yamamoto; Animesh Nandi; Kevin P Rosenblatt; Michel G Baum; Susan Schiavi; Ming-Chang Hu; Orson W Moe; Makoto Kuro-o
Journal:  J Biol Chem       Date:  2006-01-25       Impact factor: 5.157

4.  Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism.

Authors:  Keisuke Kobayashi; Yasuo Imanishi; Akimitsu Miyauchi; Naoyoshi Onoda; Takehisa Kawata; Hideki Tahara; Hitoshi Goto; Takami Miki; Eiji Ishimura; Toshitsugu Sugimoto; Tetsuro Ishikawa; Masaaki Inaba; Yoshiki Nishizawa
Journal:  Eur J Endocrinol       Date:  2006-01       Impact factor: 6.664

5.  1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport.

Authors:  Olga I Kolek; Eric R Hines; Marci D Jones; Loren K LeSueur; Maciej A Lipko; Pawel R Kiela; James F Collins; Mark R Haussler; Fayez K Ghishan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-07-14       Impact factor: 4.052

6.  Fibroblast growth factor-23 is regulated by 1alpha,25-dihydroxyvitamin D.

Authors:  Michael T Collins; John R Lindsay; Alka Jain; Marilyn H Kelly; Carolee M Cutler; Lee S Weinstein; Jie Liu; Neal S Fedarko; Karen K Winer
Journal:  J Bone Miner Res       Date:  2005-07-18       Impact factor: 6.741

7.  Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules.

Authors:  Michel Baum; Susan Schiavi; Vangipuram Dwarakanath; Raymond Quigley
Journal:  Kidney Int       Date:  2005-09       Impact factor: 10.612

8.  Fibroblast growth factor 23 concentrations in humoral hypercalcemia of malignancy and hyperparathyroidism.

Authors:  Ravinder J Singh; Rajiv Kumar
Journal:  Mayo Clin Proc       Date:  2003-07       Impact factor: 7.616

9.  Serum FGF23 levels in normal and disordered phosphorus homeostasis.

Authors:  Thomas J Weber; Shiguang Liu; Olafur S Indridason; L Darryl Quarles
Journal:  J Bone Miner Res       Date:  2003-07       Impact factor: 6.741

10.  FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting.

Authors:  Mara Riminucci; Michael T Collins; Neal S Fedarko; Natasha Cherman; Alessandro Corsi; Kenneth E White; Steven Waguespack; Anurag Gupta; Tamara Hannon; Michael J Econs; Paolo Bianco; Pamela Gehron Robey
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

View more
  50 in total

Review 1.  Biology of Fibroblast Growth Factor 23: From Physiology to Pathology.

Authors:  Marie Courbebaisse; Beate Lanske
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

2.  RAS in FGF23: another piece in the puzzle.

Authors:  Diana Ovejero; Michael T Collins
Journal:  J Clin Endocrinol Metab       Date:  2014-01       Impact factor: 5.958

3.  Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome.

Authors:  Mary Scott Ramnitz; Pravitt Gourh; Raphaela Goldbach-Mansky; Felasfa Wodajo; Shoji Ichikawa; Michael J Econs; Kenneth E White; Alfredo Molinolo; Marcus Y Chen; Theo Heller; Jaydira Del Rivero; Patricia Seo-Mayer; Bita Arabshahi; Malaka B Jackson; Sarah Hatab; Edward McCarthy; Lori C Guthrie; Beth A Brillante; Rachel I Gafni; Michael T Collins
Journal:  J Bone Miner Res       Date:  2016-09-20       Impact factor: 6.741

4.  PTH Regulation of FGF23 Fragments: A Tail in Two Acts

Authors:  Larry J Suva; Peter A Friedman
Journal:  Endocrinology       Date:  2017-04-29       Impact factor: 4.736

5.  Stability and degradation of fibroblast growth factor 23 (FGF23): the effect of time and temperature and assay type.

Authors:  D El-Maouche; C E Dumitrescu; P Andreopoulou; R I Gafni; B A Brillante; N Bhattacharyya; N S Fedarko; M T Collins
Journal:  Osteoporos Int       Date:  2016-02-29       Impact factor: 4.507

Review 6.  The PTH-Vitamin D-FGF23 axis.

Authors:  Jenny E Blau; Michael T Collins
Journal:  Rev Endocr Metab Disord       Date:  2015-06       Impact factor: 6.514

7.  Tumor-induced osteomalacia: experience from a South American academic center.

Authors:  G González; R Baudrand; M F Sepúlveda; N Vucetich; F J Guarda; P Villanueva; O Contreras; A Villa; F Salech; L Toro; L Michea; P Florenzano
Journal:  Osteoporos Int       Date:  2017-03-25       Impact factor: 4.507

8.  MC4R-dependent suppression of appetite by bone-derived lipocalin 2.

Authors:  Ioanna Mosialou; Steven Shikhel; Jian-Min Liu; Antonio Maurizi; Na Luo; Zhenyan He; Yiru Huang; Haihong Zong; Richard A Friedman; Jonathan Barasch; Patricia Lanzano; Liyong Deng; Rudolph L Leibel; Mishaela Rubin; Thomas Nickolas; Wendy Chung; Lori M Zeltser; Kevin W Williams; Jeffrey E Pessin; Stavroula Kousteni
Journal:  Nature       Date:  2017-03-08       Impact factor: 49.962

Review 9.  Fibrous dysplasia and fibroblast growth factor-23 regulation.

Authors:  Alison M Boyce; Nisan Bhattacharyya; Michael T Collins
Journal:  Curr Osteoporos Rep       Date:  2013-06       Impact factor: 5.096

10.  Posttranslational processing of FGF23 in osteocytes during the osteoblast to osteocyte transition.

Authors:  Hiroyuki Yamamoto; Bruno Ramos-Molina; Adam N Lick; Matthew Prideaux; Valeria Albornoz; Lynda Bonewald; Iris Lindberg
Journal:  Bone       Date:  2015-12-31       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.